Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZMO -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (34)	2/12/1999 9:39:00 AM
From: jeffbas	Read Replies (1) \| Respond to of 438

Here is a logical analysis from a non-scientist on which I would be interested in hearing critical comment, particularly from an ENMD shareholder: 1. CEO of GZMO calls their Folkman product "next generation" (Boston Globe). 2. In view of known controversy on ENMD products, I assume that GZMO would have done major due diligence on new one and that their scientists believe it is at least as good, and probably better. 3. GENZ parent company relationship puts GZMO in a better position to produce, test, finance and market their product than ENMD. 4. Independent confirmation of Endostatin product of ENMD having positive biological effect in animals caused ENMD market cap to rise $130 million yesterday. 5. GZMO was about $3 before their announcement. My conclusion is that once a favorable scientific article appears in a leading journal on GZMO's new Folkman product, which should be a foregone conclusion, GZMO market cap should increase from the $3 starting point by at least as much as ENMD $130 million increase. As best as I can determine from the latest GENZ 10Q, GZMO appears to have about 20 million fully diluted shares. Therefore, that suggests to me that if ENMD is worth $25, GZMO is worth about $10.